Latest Breaking News On - Fruquintinib development beyond - Page 1 : comparemela.com

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of Fruquintinib in Refractory Metastatic Colorectal Cancer from the Upcoming ESMO 2022 Presentation
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesIsrael generalHong kongFrance generalSouth koreaCity ofUnited kingdomComunidad autonoma de catalunaZhou yiAtholl tweedie freddy crossleyTakayuki yoshinoBen atwell alex shawMark leeEllenf kniselyArvind dasari

HUTCHMED Highlights Phase III FRESCO-2 MRCT Data Summary of

Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) Increased disease control with risk of disease.

New yorkUnited statesIsrael generalHong kongFrance generalSouth koreaCity ofUnited kingdomComunidad autonoma de catalunaZhou yiAtholl tweedie freddy crossleyTakayuki yoshinoBen atwell alex shawMark leeEllenf kniselyArvind dasari

HUTCHMED (China) (HCM) to Present Additional Fruquintinib MRCT FRESCO-2 Data

HUTCHMED (China) (HCM) to Present Additional Fruquintinib MRCT FRESCO-2 Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesFrance generalHong kongSouth koreaCity ofUnited kingdomZhou yiAtholl tweedie freddy crossleyBen atwell alex shawMark leeArvind dasariDavidh johnsonCathy engAnnie chengDivision of cancer medicine

HUTCHMED Highlights Fruquintinib MRCT FRESCO-2 Data to be Presented at the Upcoming ESMO Congress 2022

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

New yorkUnited statesFrance generalHong kongSouth koreaCity ofUnited kingdomZhou yiAtholl tweedie freddy crossleyBen atwell alex shawMark leeArvind dasariDavidh johnsonCathy engAnnie chengDivision of cancer medicine

HUTCHMED Completes Planned Enrollment of FRESCO-2, a Global

Recruitment of 687 patients globally completed in fifteen months, ahead of schedule FRESCO-2 primary objective is to confirm overall.

United statesMarek kaniaEli lillyFruquintinib development beyondInternational corporationDrug administrationJournal of the american medical associationChina limitedChina national medical products administrationJapanese pharmaceuticalsEuropean medicines agencyChina national reimbursement drug listDevices agencyManaging directorChief medical officerMedical devices agency